GLP‑1 drug for overweight cats
Cornell launched an 11‑week trial testing AKS‑562c, a once‑weekly GLP‑1 Fc‑fusion drug aimed at reducing appetite and body weight in client‑owned cats. The study is focused on safety, tolerability and meaningful weight loss — a reminder that GLP‑1 approaches are expanding beyond human medicine into veterinary care (dvm360.com).
Glucagon-like peptide-1 is a gut hormone that tells the brain and stomach a meal has happened, so eating slows down before the body takes in too many calories. In people, drugs that copy that signal have turned into some of the most successful weight-loss medicines in decades. (dvm360.com) Cats have the same basic appetite-control wiring, but feline weight loss has mostly depended on smaller meals, special diets, and owners sticking to a plan every day. Cornell says those plans often work in laboratory settings but often fail in real homes because both cat behavior and owner routines get in the way. (vet.cornell.edu) That gap is big enough to matter because 61% of cats evaluated by veterinary professionals in the United States in 2022 were classified as overweight or having obesity. Cornell’s project description says excess weight raises the risk of diabetes mellitus and arthritis and is linked to shorter lifespan. (petobesityprevention.org, vet.cornell.edu) Now Cornell University College of Veterinary Medicine is testing a cat-specific candidate called AKS-562c in client-owned cats over 11 weeks. The study is asking a simple question: can a once-weekly shot reduce appetite enough to produce real weight loss without causing side effects owners and veterinarians cannot live with. (dvm360.com, vet.cornell.edu) The once-weekly part is the engineering trick. Akston says AKS-562c is an Fc-fusion protein, which means the appetite signal is attached to a larger protein fragment so it stays in the body longer, like putting a small note inside a sturdier envelope that survives the mail. (akstonbio.com) Cornell’s earlier laboratory-cat work is the reason this moved into owned pets. The university says preclinical studies found the drug was safe and effective at limiting food intake, and Akston says drug-level testing supported weekly dosing. (vet.cornell.edu, akstonbio.com) The trial is not treating the drug as a magic replacement for diet control. Cornell and dvm360 both describe it as an adjunct to nutritional management, which means the medicine is being tested alongside food planning rather than instead of it. (dvm360.com, vet.cornell.edu) The owners matter almost as much as the cats here. Akston says the study is screening its first cats, aims to enroll 70, and can expand to 140, which gives researchers a chance to see how a weekly obesity drug performs in the messy reality of missed schedules, picky eating, and multi-cat households. (akstonbio.com) This is also one of the clearest signs that the glucagon-like peptide-1 boom is moving beyond human medicine into veterinary care. Akston says it is already working on a similar dog program that trails the cat program by about six months, so pet obesity is starting to look like a real drug category instead of a one-off experiment. (akstonbio.com) If AKS-562c works, the win is not that cats become tiny versions of human weight-loss patients. The win is that veterinarians might finally get a practical once-a-week tool for a condition that is common, chronic, and hard to manage one measuring cup at a time. (dvm360.com, vet.cornell.edu)
